Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|June 21, 2013
Challenges with Solubility and Bioavailability Video, Part 1
Rita Peters talks with Jeffery C. Basham, vice president, business development at Metrics about the pharmaceutical industry's challenges with solubility and bioavailability. The video was recorded live at the Interphex 2013 trade show. In this video they discuss the factors that have contributed to the rise in the number of poorly-water soluble compounds in development
Advertisement
Recorded live at the Interphex 2013 trade show, Rita Peters asks Jeffery C. Basham, vice president, business development: From your experience, do you find that the related project work for solubility/bioavailability enhancement is mostly applied for new drug development or do you see it also driving growth in projects for product lifecycle management, for example, to improve dosing schemes/regimes? Can you provide an example of either case?
Check out the rest of the interview:
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
2
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
3
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
4
PharmTech’s Weekly Roundup—September 25, 2026
5